Related Experiment Video
Updated: Apr 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars in Dermatology: Current Situation (Part II)
L Puig1, G Carretero2, E Daudén3
1Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.
Abstract:
The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more biosimilars can be expected to follow in the coming months and years. Logically, this new situation will have economic repercussions and alter prescribing patterns among dermatologists. In this second part of the review, we will look at several somewhat contentious issues, such as the extrapolation of indications, interchangeability, and automatic substitution. We will also review the biosimilars with indications for psoriasis currently in the clinical development pipeline and assess their potential to offer comparable efficacy and safety to the reference product while contributing to the sustainability of the public health care system.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Equivalents
Bioequivalence studies: Biowaivers
Clinical Applications of Epidermal Stem Cells

